Key result
This review summarizes the current understanding of the pathophysiology, non-invasive imaging detection, and treatment of cardiac allograft vasculopathy in heart transplant recipients.
Why the study?
Cardiac allograft vasculopathy is a main cause of death beyond the first year after heart transplantation, and a better understanding is crucial to improving long-term outcomes.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiology, detection, and treatment of cardiac allograft vasculopathy to improve long-term outcomes in heart transplant recipients.
One of the main causes of death beyond the first year after heart transplantation is cardiac allograft vasculopathy (CAV). This review summarises the current understanding of its complex pathophysiology, detection and treatment, including the available data on non-invasive imaging modalities used for screening and diagnosis. A better understanding of this entity is crucial to improving the long-term outcomes of the growing population of patients with a heart transplant.
No takes yet. Share an insight, caveat, or question.
Ortega–Legaspi et al. (2021) conducted a review in Cardiac allograft vasculopathy. Diagnosis and management strategies was evaluated. This review summarizes the current understanding of the pathophysiology, non-invasive imaging detection, and treatment of cardiac allograft vasculopathy in heart transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: